EUVIMEDEUVIMED entdecken
Crossref

Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients

Josef E Gillson, Sooin Byeon, Angela Chou, Sarah Maloney, Nick Pavlakis, Stephen J Clarke, David L Chan, Connie I Diakos, Anthony J Gill, Jaswinder S Samra, Anubhav Mittal, Sumit Sahni iD

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.14341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Josef E Gillson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Northern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ramsay Research and Teaching Fund, PanKind, The Australian Pancreatic Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant chemotherapy (NAC) can provide improved survival outcomes in pancreatic ductal adenocarcinoma (PDAC) patients who respond to treatment, but currently available biomarkers cannot reliably predict NAC response. This study aimed to determine the potential of a previously identified diagnostic and prognostic biomarker panel (i.e. Ca‐125, S100A2, S100A4, Mesothelin and Ca19‐9) for the monitoring of NAC‐response in PDAC patients.

Methods

This single‐centre, retrospective study, utilised serum from NAC treated PDAC patients to determine the levels of biomarkers by Enzyme‐Linked Immunosorbent Assay (ELISA). The percentage of the tumour bed occupied by viable carcinoma (PVC) was used to divide patients into good (PVC < 50%) and poor (PVC ≥ 50%) NAC‐responders. Statistical analysis was performed to measure the ability of individual biomarkers and a biomarker panel in NAC treatment response and patient survival.

Results

Serum specimens from a total of 108 PDAC patients were assessed. Ca‐125, Ca19‐9 and S100A2 showed a significant positive correlation with PVC. Ca‐125 demonstrated a superior ability to monitor NAC treatment response (Area under receiver operating curve (AUC): .6954) compared to the more widely used clinical biomarker, Ca19‐9 (AUC: .6291). A panel of Ca‐125 and Ca19‐9 showed good ability to monitor NAC response in PDAC patients (AUC: .7349). Patients with high levels of both Ca‐125 and Ca19‐9 were shown to have the poorest overall survival (median overall survival: 17 vs. 30 months).

Conclusion

A serum biomarker panel of Ca‐125 and Ca19‐9 could be used for effective clinical management of PDAC patients undergoing NAC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalBiomarkers, TumorHumansMaleFemaleMiddle AgedNeoadjuvant TherapyCA-19-9 AntigenRetrospective StudiesAgedCA-125 AntigenGPI-Linked ProteinsMesothelinS100 ProteinsS100 Calcium-Binding Protein A4AdultTreatment OutcomeROC CurveChemotherapy, AdjuvantPrognosisEnzyme-Linked Immunosorbent AssayChemotactic Factors

Stichwörter der Autor:innen

biomarkerschemoresistanceneoadjuvant chemotherapypancreatic ductal adenocarcinomatreatment response

Substanzen

Biomarkers, TumorCA-19-9 AntigenCA-125 AntigenGPI-Linked ProteinsMesothelinS100 ProteinsS100A2 protein, humanS100 Calcium-Binding Protein A4S100A4 protein, humanChemotactic Factors

Autor:innen und Institutionen

  • Northern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia.
  • Kolling Institute of Medical Research, University of Sydney, St Leonards, New South Wales, Australia.
  • NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Australian Pancreatic Centre, St Leonards, Sydney, New South Wales, Australia.
  • Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Sumit Sahni

Förderung

  • Ramsay Research and Teaching Fund
  • PanKind, The Australian Pancreatic Cancer Foundation

Zitieren

APA

Gillson, J. E., Byeon, S., Chou, A., Maloney, S., Pavlakis, N., Clarke, S. J., Chan, D. L., Diakos, C. I., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2025). Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14341

Vancouver

Gillson JE, Byeon S, Chou A, Maloney S, Pavlakis N, Clarke SJ, et al. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.14341

BibTeX
@article{Gillson2025,
  author = {Gillson, Josef E and Byeon, Sooin and Chou, Angela and Maloney, Sarah and Pavlakis, Nick and Clarke, Stephen J and Chan, David L and Diakos, Connie I and Gill, Anthony J and Samra, Jaswinder S and Mittal, Anubhav and Sahni, Sumit},
  title = {Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.14341}
}
Kostenlos starten →